Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SCYX 
Scynexis Inc (SCYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCYX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.72% | Avg. Invested days 13 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.63M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 3 | Beta 1.64 | 52 Weeks Range 0.66 - 1.66 | Updated Date 08/29/2025 |
52 Weeks Range 0.66 - 1.66 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.2 | Actual -0.14 |
Profitability
Profit Margin - | Operating Margin (TTM) -700.95% |
Management Effectiveness
Return on Assets (TTM) -27.12% | Return on Equity (TTM) -37.22% |
Valuation
Trailing PE - | Forward PE 2.09 | Enterprise Value -6768186 | Price to Sales(TTM) 10.94 |
Enterprise Value -6768186 | Price to Sales(TTM) 10.94 | ||
Enterprise Value to Revenue 0.44 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 41924900 | Shares Floating 37569359 |
Shares Outstanding 41924900 | Shares Floating 37569359 | ||
Percent Insiders 2.08 | Percent Institutions 26.58 |
Upturn AI SWOT
Scynexis Inc
Company Overview
History and Background
Scynexis, Inc. is a biotechnology company focused on developing and commercializing novel anti-infectives to address unmet medical needs. Founded in 1999, the company has focused on developing therapies to overcome resistant infections.
Core Business Areas
- Anti-infective Development and Commercialization: Scynexis is engaged in the discovery, development, and commercialization of novel anti-infective therapies. Currently, its primary focus is on its approved drug, BREXAFEMME (ibrexafungerp).
Leadership and Structure
The leadership team includes David Angulo, M.D., as President and CEO. The organizational structure typically involves research, development, regulatory, commercial, and administrative departments.
Top Products and Market Share
Key Offerings
- BREXAFEMME (ibrexafungerp): BREXAFEMME is an oral antifungal medication approved for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. Market share data is dynamic, but Scynexis is actively working to expand its market presence. Competitors include azole antifungals like fluconazole (Diflucan), which is available generically.
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of drug-resistant infections and the need for new treatment options. There is a strong demand for novel antifungal therapies.
Positioning
Scynexis aims to be a leader in developing and commercializing novel anti-infective therapies, particularly in the antifungal space. Its competitive advantage lies in BREXAFEMME's novel mechanism of action and oral formulation.
Total Addressable Market (TAM)
The TAM for VVC treatment is significant, given the high prevalence of the condition. Scynexis is positioned to capture a portion of this market with BREXAFEMME, targeting both patients and healthcare providers.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action of ibrexafungerp
- Oral formulation of BREXAFEMME offers convenience
- Focus on unmet medical needs in anti-infectives
Weaknesses
- Reliance on a single approved product (BREXAFEMME)
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Need for further clinical trials to expand indications
Opportunities
- Expansion of ibrexafungerp indications (e.g., invasive fungal infections)
- Strategic partnerships for commercialization
- Development of new anti-infective therapies
Threats
- Competition from established antifungal therapies (e.g., azoles)
- Generic entry of existing antifungals
- Regulatory hurdles for new drug approvals
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
Scynexis's advantage lies in the novel mechanism of BREXAFEMME. Disadvantages include its smaller size and limited resources compared to major pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to BREXAFEMME's launch and initial sales. The growth rate is largely dependent on market penetration and expansion of indications.
Future Projections: Future growth depends on BREXAFEMME sales, potential new indications, and the success of the pipeline. Analyst estimates are available from financial information providers.
Recent Initiatives: Recent initiatives include expanding the commercial reach of BREXAFEMME, conducting clinical trials for new indications, and exploring strategic partnerships.
Summary
Scynexis is a biotechnology company focusing on anti-infectives, primarily through its drug BREXAFEMME. The company's future depends on expanding BREXAFEMME's market and securing additional indications. Its small size compared to competitors and reliance on a single product represent key vulnerabilities. However, its novel antifungal mechanism provides a competitive advantage, and partnerships may bolster future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Scynexis Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary. Investment decisions should be based on thorough due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scynexis Inc
Exchange NASDAQ | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. David Gonzalez Angulo M.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 28 | Website https://www.scynexis.com |
Full time employees 28 | Website https://www.scynexis.com | ||
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.